These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29404874)

  • 1. Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis.
    Brunetti ND; Tarantino N; De Gennaro L; Correale M; Santoro F; Di Biase M
    J Thromb Thrombolysis; 2018 May; 45(4):550-556. PubMed ID: 29404874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis.
    Renda G; Ricci F; De Caterina R
    Am J Med; 2017 Apr; 130(4):457-461. PubMed ID: 27751896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis.
    Gupta S; Um KJ; Pandey A; McIntyre WF; Ivanova M; Allahverdi Y; Agahi P; Pandya F; Lopez A; Sachdeva A; Whitlock RP; Belley-Cote EP
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):339-352. PubMed ID: 31011880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
    Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: A systematic review and meta-analysis of the literature.
    Dentali F; Botto GL; Gianni M; Ambrosino P; Di Minno MN
    Int J Cardiol; 2015 Apr; 185():72-7. PubMed ID: 25791094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
    Trujillo TC; Dobesh PP; Crossley GH; Finks SW
    Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis.
    Telles-Garcia N; Dahal K; Kocherla C; Lip GYH; Reddy P; Dominic P
    Int J Cardiol; 2018 Oct; 268():143-148. PubMed ID: 30041779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin.
    Frederiksen AS; Albertsen AE; Christesen AMS; Vinter N; Frost L; Møller DS
    Europace; 2018 Jul; 20(7):1078-1085. PubMed ID: 28655151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials.
    Andò G; Trio O; Carerj S
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):577-83. PubMed ID: 25797595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation electrical cardioversion: An update systematic review and meta-analysis.
    Troisi F; Guida P; Vitulano N; Quadrini F; Di Monaco A; Grimaldi M
    Int J Cardiol; 2023 May; 379():40-47. PubMed ID: 36907451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
    Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
    Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
    Piccini JP; Stevens SR; Lokhnygina Y; Patel MR; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Breithardt G;
    J Am Coll Cardiol; 2013 May; 61(19):1998-2006. PubMed ID: 23500298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis.
    Mariani MV; Magnocavallo M; Straito M; Piro A; Severino P; Iannucci G; Chimenti C; Mancone M; Rocca DGD; Forleo GB; Fedele F; Lavalle C
    J Thromb Thrombolysis; 2021 Feb; 51(2):419-429. PubMed ID: 33044735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis.
    Sen P; Kundu A; Sardar P; Chatterjee S; Nairooz R; Amin H; Aronow WS
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):33-41. PubMed ID: 26138204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis.
    Caldeira D; Costa J; Ferreira JJ; Lip GY; Pinto FJ
    Clin Res Cardiol; 2015 Jul; 104(7):582-90. PubMed ID: 25643952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yan BP; Yu CM
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):23-35. PubMed ID: 23224686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.